Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep + PARP inhibitors = enhanced sensitization

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 20, 2024 8:29pm

121 Views

Post# 35837644

RE:RE:ONCY pelareorep + PARP inhibitors = enhanced sensitization

Numerous clinical trials are ongoing to develop next-generation PARPi and validate the use of combination therapies, particularly the potential synergistic effect of PARPi with ICIs.

Additional studies are necessary to investigate potential PARPi combinations in groups of patients who have clinically unmet anticancer needs, including patients who do not respond well to established PARPi/ICI monotherapies.

Biomarkers are critical in identifying optimal patient populations.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing